STANDARD BIOTOOLS INC.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
LAB$0.64+2.2%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $267,487 | $120,863 |
| Short-term investments | 193,624 | 66,712 |
| Accounts receivable, net | 12,982 | 13,431 |
| Inventory | 17,617 | 19,981 |
| Prepaid expenses and other current assets | 5,592 | 4,871 |
| Current assets held for sale | — | 228,406 |
| Total current assets | 497,302 | 454,264 |
| Property and equipment, net | 13,240 | 19,275 |
| Operating lease right-of-use asset, net | 23,083 | 26,732 |
| Other non-current assets | 3,194 | 3,154 |
| Long-term investments | 98,240 | 25,701 |
| Deferred tax asset, non-current | 273 | 38,628 |
| Total assets | $635,332 | $567,754 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $3,453 | $5,407 |
| Accrued liabilities | 30,436 | 29,783 |
| Operating lease liabilities, current | 5,691 | 5,490 |
| Deferred revenue, current | 8,814 | 38,949 |
| Deferred grant income, current | 2,627 | 3,046 |
| Current liabilities held for sale | — | 25,633 |
| Total current liabilities | 51,021 | 108,308 |
| Convertible notes, non-current | 300 | 299 |
| Deferred tax liability | 823 | 810 |
| Operating lease liabilities, non-current | 20,843 | 25,038 |
| Deferred revenue, non-current | 3,102 | 3,503 |
| Deferred grant income, non-current | 2,372 | 4,290 |
| Other non-current liabilities | 1,121 | 1,215 |
| Total liabilities | 79,582 | 143,463 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.001 par value, 10,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding at September 30, 2026 and December 31, 2025 | — | — |
| Common stock: $0.001 par value, 600,000 shares authorized at September 30, 2026 and December 31, 2025; 413,251 and 404,961 shares issued at September 30, 2026 and December 31, 2025, respectively; 394,671 and 386,381 shares outstanding at September 30, 2026 and December 31, 2025, respectively | 413 | 404 |
| Additional paid-in capital | 1,748,204 | 1,732,393 |
| Accumulated other comprehensive income (loss) | 354 | (1,492) |
| Accumulated deficit | (1,146,754) | (1,260,547) |
| Treasury stock at cost: 18,580 shares at September 30, 2026 and December 31, 2025 | (46,467) | (46,467) |
| Total stockholders’ equity | 555,750 | 424,291 |
| Total liabilities and stockholders’ equity | $635,332 | $567,754 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.